Inform Genomics, Tesaro to Assess Risk of Chemotherapy Side Effects | GenomeWeb

NEW YORK (GenomeWeb News) – Inform Genomics said today it has reached a deal with Tesaro to evaluate the risk of chemotherapy-induced nausea and vomiting in patients.

Using Inform Genomics' bioinformatics and genomic platforms, Tesaro will assess the risk of nausea and vomiting in patients receiving certain "moderately" emetogenic chemotherapy regimens and standard antiemetic therapy, without an NK-1 receptor antagonist, Inform said.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.